Drug Trial Radar · NCT04401579
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
Last checked: Nov 19, 2026Latest source record: Mar 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,033
Actual
Start
May 8, 2020
Primary completion
Jul 31, 2020
Study completion Jul 31, 2020
Sponsor
- Sponsor type
- NIH
- First posted
- May 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACTT-2 will evaluate the combination of baricitinib and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary outcome is time to recovery by Day 29.
Conditions
- COVID-19
Interventions
PlaceboOther
The matching Baricitinib placebo contains lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The coating for the placebo tablet is identical to that of the corresponding active tablet.
RemdesivirDrug
Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
BaricitinibDrug
Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to RecoveryTime frame: Day 1 through Day 29
- Time to Recovery by RaceTime frame: Day 1 through Day 29
- Time to Recovery by EthnicityTime frame: Day 1 through Day 29
- Time to Recovery by SexTime frame: Day 1 through Day 29
Locations
71 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine - Infectious Disease
Birmingham, Alabama
University of California San Diego Health - Jacobs Medical Center
La Jolla, California
University of California Los Angeles Medical Center - Westwood Clinic
Los Angeles, California
University of California Irvine Medical Center - Infectious Disease
Orange, California
VA Palo Alto Health Care System - Infectious Diseases
Palo Alto, California
Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases
Palo Alto, California
University of California Davis Medical Center - Internal Medicine - Infectious Disease
Sacramento, California
Naval Medical Center San Diego - Infectious Disease Clinic
San Diego, California
University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine
San Francisco, California
Cedars Sinai Medical Center
West Hollywood, California
Eastern Colorado Health Care System
Aurora, Colorado
Denver Health Division of Hospital Medicine - Main Campus
Denver, Colorado
Georgetown University Medical Center - Division of Infectious Diseases
Washington D.C., District of Columbia
University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine
Gainesville, Florida
University of Miami Miller School of Medicine - Infectious Diseases
Miami, Florida
Emory Vaccine Center - The Hope Clinic
Decatur, Georgia
Atlanta VA Medical Center - Infectious Diseases Clinic
Decatur, Georgia
Northwestern Hospital - Infectious Disease
Chicago, Illinois
University of Illinois at Chicago College of Medicine - Division of Infectious Diseases
Chicago, Illinois
Indiana University School of Medicine - Infectious Diseases
Indianapolis, Indiana
Ochsner Medical Center - Kenner - Department of Infectious Diseases
Kenner, Louisiana
Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases
New Orleans, Louisiana
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore
Baltimore, Maryland
Johns Hopkins Hospital - Medicine - Infectious Diseases
Baltimore, Maryland
Walter Reed National Military Medical Center
Bethesda, Maryland
National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section
Bethesda, Maryland
Massachusetts General Hospital - Infectious Diseases
Boston, Massachusetts
University of Massachusetts Medical School - Infectious Diseases and Immunology
Worcester, Massachusetts
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine
Minneapolis, Minnesota
Saint Louis University - Center for Vaccine Development
St Louis, Missouri
University of Nebraska Medical Center - Infectious Diseases
Omaha, Nebraska
University of New Mexico Clinical and Translational Science Center
Albuquerque, New Mexico
New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology
New York, New York
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York
Montefiore Medical Center - Infectious Diseases
The Bronx, New York
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit
Durham, North Carolina
Womack Army Medical Center - Pulmonary and Respiratory Services
Fort Bragg, North Carolina
Kaiser Permanente Northwest - Center for Health Research
Portland, Oregon
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases
Hershey, Pennsylvania
University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology
Philadelphia, Pennsylvania
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.